Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03574363 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
A Phase 2 study, sponsored by KBP Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT03574363 is a Phase 2 study that has completed, run by KBP Biosciences. The registered enrollment target is 162 participants.
The verdict
NCT03574363, a Phase 2 study, has completed, sponsored by KBP Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
This is a Phase 2 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy, safety, and pharmacokinetics of KBP-5074 in patients with moderate-to-severe chronic kidney disease and uncontrolled hypertension.
Interventions
- DRUG KBP-5074 0.25 mg tablet
- DRUG KBP-5074 0.5 mg tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2018-04-25 |
| Est. Completion | 2020-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03574363
The ClinicalTrials.gov registry entry for NCT03574363 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is KBP Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which KBP-5074 0.25 mg tablet is the first listed.
NCT03574363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03574363 about?
NCT03574363 is a clinical study titled "Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease". This is a Phase 2 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy, safety, and pharmacokinetics of KBP-5074 in patients with moderate-to-severe chronic kidney disease and uncontrolled hypertension.
What is the current status of trial NCT03574363?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2018-04-25. Estimated completion is 2020-08-05.
What interventions are being tested in trial NCT03574363?
The interventions under investigation include: KBP-5074 0.25 mg tablet (DRUG), KBP-5074 0.5 mg tablet (DRUG).
Who is sponsoring clinical trial NCT03574363?
This trial is sponsored by KBP Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.